

Exceptional speaker line-up for Ophthalmic Drugs

Hear from Santen, Novaliq GmBh, Aptar Pharma and more

LONDON, UNITED KINGDOM, October 16, 2017 /EINPresswire.com/ -- Only 6 weeks remain until Europe's Leading Ophthalmic Drugs Conference and here is why you cannot afford to miss out! www.ophthalmicdrugs.com/ein

With incredible representation from our pharma industry experts, they will help tackle every possible obstacle you may face through real-life case studies. Gain insight into latest approaches in key areas such as ocular diseases, drug delivery, pre-clinical and clinical trials, computer technologies and therapies for diabetic macular oedema.

Agenda highlights will include a spotlight on therapies for glaucoma, development

of efficient drug delivery systems and current trends in novel non-surgical interventions.



Spotlight:

Minimally Invasive Glaucoma Surgery for various glaucoma treatments will address the use of conjugate drugs and a new <u>prostaglandin</u> drug product co-developed by Santen, called '<u>Omidenepag Isopropyl</u>.' - Naj Sharif, Executive Director in R&D, Head, Global Alliances & External Research, Santen Inc

Non-Aqueous, preservative-free ocular drug delivery technology with unique properties:

One of the biggest challenges currently facing the pharmaceutical industry is the development of more efficient drug delivery systems. For instance, the anterior part of the eye is amongst the most readily accessible organs, in terms of location in the human body; however, drug delivery to eye tissue is particularly problematic. This is reflected by the notoriously poor bioavailability of topical ocular drug formulations of 5% or less. - Bernhard Guenther, Co-Founder, Chief Innovation Officer, Novaliq GmbH

New Technologies in Ophthalmic Drug Delivery:

Poor Patient Compliance is a major impediment to effective treatments in eye care. By bringing in new

technologies will help ease the situation and enable patients to become comfortable during treatment. Also, monitoring systems for clinical trials are a revolutionary method to ease work of clinicians and make clinical data more reliable. Other factors to be discussed are the novel drug delivery systems and how they can contribute to patient adherence, which have been approved by the FDA. - Matthias Birkhoff, Vice President Business Development, Aptar Pharma

Companies Attending:

Santen Inc, Shire, Novartis, Roche, NightstaRx, Aerie Pharmaceuticals, Bayer, Envisia Therapeutics, Boehringer Ingelheim, Oxford BioMedica, Novaliq GmbH, Alimera Sciences, Aptar Pharma and PharmaMedic Consultancy Ltd and more.

Booked Last Week:

Biozep AS, NanOptima Limited, Ora Inc and Roche

Further information is available at: www.ophthalmicdrugs.com/ein

For those looking to attend there is currently a £100 <u>early-bird</u> saving by October 31st

SMi Presents the Launch of...

Ophthalmic Drugs

Date: 28th – 29th November 2017 Location: Kensington, London

Website: www.ophthalmicdrugs.com/ein

Sponsored by: Leica Microsystems | Experimentica

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smionline.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Pav Solanki SMi Group 2078276048 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the

company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.